Medicis Pharmaceutical Corp. (MRX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $68.92 +0.79%
EPS Growth %: +27.1%
Financial Fact:
Gross profit: 160.59M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +27.1%
Financial Fact:
Gross profit: 160.59M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q3 EPS of $0.96, $0.02 better than the analyst estimate of $0.94. Revenue for the quarter came in at $484.6 million versus the consensus estimate of $475.84 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- Walmart stock climbs on AI shopping tool expansion
- Midterm 2026 Healthcare Ballot Results and Impacts Across 13 States: Black Book Research Follow-Up
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
